Results 1 to 10 of about 18,490 (188)
Bispecific antibodies and their applications [PDF]
Journal of Hematology & Oncology, 2015 Bispecific antibodies (BsAbs) recognize two different epitopes. This dual specificity opens up a wide range of applications, including redirecting T cells to tumor cells, blocking two different signaling pathways simultaneously, dual targeting of different disease mediators, and delivering payloads to targeted sites.
Mingju Hao +3 more
openaire +3 more sources
The making of bispecific antibodies [PDF]
mAbs, 2017 During the past two decades we have seen a phenomenal evolution of bispecific antibodies for therapeutic applications. The 'zoo' of bispecific antibodies is populated by many different species, comprising around 100 different formats, including small molecules composed solely of the antigen-binding sites of two antibodies, molecules with an IgG ...
Ulrich Brinkmann, Roland E. Kontermann
openaire +3 more sources
Hematology, 2023 Abstract Management of hematological malignancies is rapidly evolving from chemotherapy-based regimens toward targeted agents and immunotherapies, including bispecific antibodies (BsAbs). These novel and highly active treatments come with new side effect profiles.
de Assis, Luiz Henrique +2 more
openaire +3 more sources
Design and Production of Bispecific Antibodies [PDF]
Antibodies, 2019 With the current biotherapeutic market dominated by antibody molecules, bispecific antibodies represent a key component of the next-generation of antibody therapy. Bispecific antibodies can target two different antigens at the same time, such as simultaneously binding tumor cell receptors and recruiting cytotoxic immune cells.
Qiong Wang +7 more
openaire +4 more sources
Drug Discovery Today, 2015 Bispecific antibodies have emerged as molecules with a multitude of ...
Kontermann, Roland E., Brinkmann, Ulrich
openaire +3 more sources
Bispecific antibodies for viral immunotherapy [PDF]
Human Vaccines & Immunotherapeutics, 2017 Bispecific antibody engineering, in which binding specificities toward 2 distinct epitopes are combined into a single molecule, can greatly enhance immunotherapeutic properties of monoclonal antibodies. While the bispecific antibody approach has been applied widely to targets for indications such as cancer and inflammation, the development of such ...
Elisabeth K. Nyakatura +2 more
openaire +4 more sources
Bispecific antibodies in cancer immunotherapy [PDF]
Therapeutic Advances in Vaccines and Immunotherapy, 2018 Following the clinical success of immune checkpoint antibodies targeting CTLA-4, PD-1 or PD-L1 in cancer treatment, bispecific antibodies are now emerging as a growing class of immunotherapies with potential to further improve clinical efficacy and safety.
Eva Dahlén +2 more
openaire +3 more sources
Bispecific antibodies in cancer immunotherapy [PDF]
Human Vaccines & Immunotherapeutics, 2016 Cancer immunotherapy has recently generated much excitement after the continuing success of the immunomodulating anti-CTLA-4 and anti-PD-1 antibodies against various types of cancers. Aside from these immunomodulating antibodies, bispecific antibodies, chimeric antigen receptor T cells, and other technologies are being actively studied.
Zhong Wang, Qing Li, Siqi Chen, Jing Li
openaire +2 more sources
Bispecific antibodies in cancer immunotherapy [PDF]
Current Opinion in Biotechnology, 2020 Among antibody-based cancer therapies, bispecific antibodies (biAbs) have gained momentum in preclinical and clinical investigations following the regulatory approvals of the trailblazing T-cell engaging biAb (T-biAb) blinatumomab. Discussed herein are recent strategies that aim at boosting the potency and mitigating the toxicity of T-biAbs, broadening
openaire +3 more sources